ArQule (ARQL) Posts Q3 Loss of $0.18, Beats Estimates; Reaffirms Guidance
More News related to ARQL
- ArQule Announces Initiation of Clinical Programs with ARQ 197 in Germ Cell Tumors and Colorectal Cancer
- ArQule (ARQL) Posts Q3 Loss of $0.18, Beats Estimates; Reaffirms Guidance
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- UBS Upgrades ArQule (ARQL) Two Notches to Buy
- ArQule (ARQL) Reports Q2 Loss of $0.19, Beats by 4c; Affirms FY09 Guidance
More News related to Earnings
- HNI Corporation (HNI) Tops Q1 EPS by 2c; Revs Light
- Team Health (TMH) Reports Mixed Q4 Results
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
ArQule, Inc. (NASDAQ: ARQL) reports Q3 loss of $0.18, versus the analyst estimate of ($0.26). Revenue for the quarter was $6.44 million, which compares to the estimate of $5.85 million.
Reaffirms guidance, sees FY09 revs of $21 - $24 million, versus $23.22 consensus.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
